Korsana Biosciences Quarterly Balance Sheet
NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Korsana Biosciences financial position
As of Jun 30, 2026, Korsana Biosciences reported total assets of $6.9 million, down 26.0% from a year earlier against total liabilities of $1.8 million. Shareholders' equity stood at $5.1 million, or 73.4% of assets. The company held $1.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 0.82, meaning short-term obligations exceed short-term assets.
Summary generated from market data by MetaCap's automated system. Methodology
Korsana Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.39M | 2.82M | 3.24M | 4.57M | 3.01M | 3.64M | 3.23M | 2.87M | 4.59M | 5.70M | 7.57M | 9.11M |
| Receivables | 0 | 0 | 1.00M | 100.00K | 525.00K | 581.00K | 556.00K | 44.00K | — | — | 0 | 0 |
| Total Current Assets | 1.51M | 3.09M | 4.63M | 5.07M | 4.02M | 4.50M | 4.22M | 3.55M | 4.71M | 6.01M | 8.02M | 9.86M |
| Property, Plant & Equipment | 66.00K | 66.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 6.93M | 8.51M | 9.98M | 10.41M | 9.37M | 9.85M | 9.57M | 8.90M | 10.06M | 11.36M | 13.37M | 15.21M |
| Accounts Payable | 1.60M | 457.00K | 508.00K | 480.00K | 462.00K | 483.00K | 390.00K | 304.00K | 651.00K | 741.00K | 1.20M | 814.00K |
| Total Current Liabilities | 1.84M | 1.71M | 900.00K | 877.00K | 800.00K | 1.07M | 725.00K | 700.00K | 1.28M | 1.44M | 2.09M | 2.34M |
| Total Liabilities | 1.84M | 1.71M | 900.00K | 877.00K | 800.00K | 1.07M | 725.00K | 700.00K | 1.28M | 1.44M | 2.09M | 2.34M |
| Shareholders' Equity | 5.09M | 6.79M | 9.09M | 9.54M | 8.57M | 8.78M | 8.85M | 8.20M | 8.78M | 9.92M | 11.29M | 12.87M |
| Retained Earnings | -275.95M | -274.20M | -271.02M | -270.22M | -269.25M | -268.92M | -267.49M | -268.02M | -267.30M | -265.96M | -264.42M | -262.72M |
| Net Cash (Debt) | 1.39M | 2.82M | 3.24M | 4.57M | 3.01M | 3.64M | 3.23M | 2.87M | 4.59M | 5.70M | 7.57M | 9.11M |
| Shares Outstanding | 4.26M | 4.24M | 3.82M | 3.70M | 3.08M | 3.06M | 2.55M | 2.53M | 2.52M | 2.50M | 2.47M | 2.45M |
This table shows 12 quarterly periods of Korsana Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow KRSA's reporting calendar. What is a balance sheet?